Robert L Levin

发表

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Rebecca Racz, David G. Strauss, D. Strauss, 2018, CPT: pharmacometrics & systems pharmacology.

Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol.

E. Phillips, C. Stone, S. Kozlowski, 2020, The journal of allergy and clinical immunology. In practice.

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

Robert L Levin, T. Laughren, 2006, Schizophrenia bulletin.

Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System

Robert L Levin, A. Brinker, L. L. La Grenade, 2017, The Journal of pediatrics.

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting

Rebecca Racz, Theodoros G Soldatos, David B Jackson, 2020, Clinical pharmacology and therapeutics.

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Michael F. Green, W. Fenton, D. Goff, 2005, Schizophrenia bulletin.

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

Sue-Jane Wang, I. Zineh, E. Unger, 2011, The Journal of clinical psychiatry.

Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

Liang Zhao, A. Mosholder, Robert L Levin, 2018, Drug Safety.

Liver injury associated with dimethyl fumarate in multiple sclerosis patients

M. Avigan, Robert L Levin, C. Kortepeter, 2017, Multiple sclerosis.

US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone.

Robert L Levin, Vicky C Chan, L. L. La Grenade, 2015, The Journal of clinical psychiatry.

Food and Drug Administration commentary on methodological issues in negative symptom trials.

Robert L Levin, T. Laughren, 2011, Schizophrenia bulletin.

Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.

E. Wu, Robert L Levin, C. Kortepeter, 2017, Journal of the American Pharmacists Association : JAPhA.

Labeling and Drug Safety Communication Approaches to Loperamide Abuse.

E. Wu, Robert L Levin, C. Kortepeter, 2017, JACC. Clinical electrophysiology.